Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 16 results.
User Information
Export Records
  1. 1.   Prednisolone pharmacokinetics in the presence and absence of Ritonavir after oral prednisone administration to healthy volunteers
  2. Penzak, S. R.; Fomnentini, E.; Alfaro, R. M.; Long, M.; Natarajan, V.; Kovacs, J.
  3. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2005, DEC 15; 40(5): 573-580.
  1. 2.   Application of InChI to curate, index, and query 3-D structures
  2. Prasanna, M. D.; Vondrasek, J.; Wlodawer, A.; Bhat, T. N.
  3. Proteins-Structure Function and Bioinformatics. 2005, JUL 1; 60(1): 1-4.
  1. 3.   Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes
  2. Penzak, S. R.; Shen, J. M.; Alfaro, R. M.; Remaley, A. T.; Natarajan, V.; Falloon, J.
  3. Therapeutic Drug Monitoring. 2004 26(3): 322-330.
  1. 4.   HIV-1 protease variants from 100-fold drug resistant clinical isolates: expression, purification, and crystallization
  2. Vickrey, J. F.; Logsdon, B. C.; Proteasa, G.; Palmer, S.; Winters, M. A.; Merigan, T. C.; Kovari, L. C.
  3. Protein Expression and Purification. 2003 28(1): 165-172.
  1. 5.   Kinetics of the dimerization of retroviral proteases: The "fireman's grip" and dimerization
  2. Ingr, M.; Uhlikova, T.; Strisovsky, K.; Majerova, E.; Konvalinka, J.
  3. Protein Science. 2003 12(10): 2173-2182.
  1. 6.   The aspartic proteinase from Saccharomyces cerevisiae folds its own inhibitor into a helix
  2. Li, M.; Phylip, L. H.; Lees, W. E.; Winther, J. R.; Dunn, B. M.; Wlodaawer, A.; Kay, J.; Gustchina, A.
  3. Nature Structural Biology. 2000 7(2): 113-117.
  1. 7.   Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain
  2. Sei, S.; Yang, Q. E.; O'Neill, D.; Yoshimura, K.; Nagashima, K.; Mitsuya, H.
  3. Journal of Virology. 2000 74(10): 4621-4633.
  1. 8.   Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: A lead HIV protease inhibitor
  2. Prasad, J.; Boyer, F. E.; Domagala, J. M.; Ellsworth, E. L.; Gajda, C.; Hamilton, H. W.; Hagen, S. E.; Markoski, L. J.; Steinbaugh, B. A.; Tait, B. D.; Humblet, C.; Lunney, E. A.; Pavlovsky, A.; Rubin, J. R.; Ferguson, D.; Graham, N.; Holler, T.; Hupe, D.; Nouhan, C.; Tummino, P. J.; Urumov, A.; Zeikus, E.; Zeikus, G.; Gracheck, S. J.; Saunders, J. M.
  3. Bioorganic & Medicinal Chemistry. 1999 7(12): 2775-2800.
  1. 9.   Structure-based design of HIV protease inhibitors: pharmacokinetic optimization
  2. Stinson, S. F.; Randad, R. S.; Clanton, D.; House, T.; Lubkowska, L.; Erickson, J. W.
  3. HIV Pathogenesis and Treatment Conference. 1998, 56 (abstract no. 2039).
  1. 10.   Importance of molecular flexibility for the resistance of HIV-1 protease inhibitors
  2. Kato, R.; Yusa, K.; Gulnik, S. V.; Bhat, T.; Hayashi, H.; Mitsuya, H.; Erickson, J. W.
  3. International Conference on AIDS. 1998, 12 67-68.
  1. 11.   Reaction Path and Free Energy Calculations of the Transition Between Alternate Conformations of Hiv-1 Protease
  2. Rick, S. W.; Erickson, J. W.; Burt, S. K.
  3. Proteins. 1998 32(1): 7-16.
  1. 12.   Molecular mechanisms of resistance: Free energy calculations of mutation effects on inhibitor binding to HIV-1 protease
  2. Rick, S. W.; Topol, I. A.; Erickson, J. W.; Burt, S. K.
  3. Protein Science. 1998 7(8): 1750-1756.
  1. 13.   Thermodynamics and proton uptake for pepstatin binding to retroviral and eukaryotic aspartic proteases
  2. Xie, D.; Gulnik, S.; Collins, L.; Gustchina, E.; Bhat, T. N.; Erickson, J. W.
  3. Advances in Experimental Medicine and Biology. 1998 436: 381-386.
  1. 14.   Application of restriction enzyme analysis to screen drug-resistant mutations in HIV-protease and in proteolytic cleavage sites in the gag region
  2. Vasudevachari, M. B.; Imamichi, T.; Imamichi, H.; Zhang, Y. M.; Salzman, N. P.
  3. Conference on Retroviruses and Opportunistic Infections. 1997, 176 (abstract no. 606).
  1. 15.   Emergence of drug resistant HIV variants with mutations in the protease gene and gag cleavage sites during indinavir therapy
  2. Zhang, Y. M.; Imamichi, H.; Falloon, J.; Lane, H. C.; Vasudevachari, M. B.; Imamichi, T.; Salzman, N. P.
  3. Conference on Retroviruses and Opportunistic Infections. 1997, 175 (abstract no. 602).
  1. 16.   Drug Resistance During Indinavir Therapy Is Caused By Mutations in the Protease Gene and in Its Gag Substrate Cleavage Sites
  2. Zhang, Y. M.; Imamichi, H.; Imamichi, T.; Lane, H. C.; Falloon, J.; Vasudevachari, M. B.; Salzman, N. P.
  3. Journal of Virology. 1997 71(9): 6662-6670.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel